

IL9

Research Grade Enokizumab

| | | | |
|---------------------------------|---|------------------|------------------|
| Catalog No. | DHD09601A DHD09601B | Quantity: | 100 µg 1.0 mg |
| Alternate Names: | Interleukin-9, IL-9, Cytokine P40, T-cell growth factor P40 | | |
| Description: | Enokizumab is a humanized monoclonal antibody targeting interleukin 9 (IL-9), being investigated for its immunomodulatory potential. | | |
| UniProt ID (target): | P15248 | | |
| Specificity: | Human IL-9 | | |
| Source: | XtenCHO cell line | | |
| Isotype: | Humanized IgG1 kappa | | |
| INN: | Enokizumab | | |
| Concentration: | 1.0 mg/ml, lot specific | | |
| Formulation: | 0.01M PBS, pH 7.4. | | |
| Purity: | > 95% as determined by SDS-PAGE | | |
| Purification: | Protein A/G affinity chromatography | | |
| Endotoxin: | ≤ 0.01 EU/µg by LAL analysis | | |
| Storage & Stability: | Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles. | | |

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

